Bronchoscopic Intratumoral Chemotherapy for Small Cell Lung Cancer (SCLC)
| Status: | Recruiting |
|---|---|
| Conditions: | Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 3/16/2015 |
| Start Date: | December 2011 |
| End Date: | December 2016 |
| Contact: | Michael Jantz, MD |
| Email: | michael.jantz@medicine.ufl.edu |
| Phone: | (866) 229-6312 |
Bronchoscopic Intratumoral Chemotherapy for Small Cell Lung Cancer
This project proposes to use bronchoscopic intratumoral chemotherapy for small cell lung
cancer in two fashions:
1. to implement a prospective clinical trial to test the feasibility and efficacy of
intralesional chemotherapy as consolidative therapy immediately following standard
systemic chemotherapy and radiation therapy for patients with limited stage SCLC by
comparing tumor growth and survival rates of the treatment group and compare the
outcomes to historical controls
2. to implement a prospective clinical trial to test the feasibility and efficacy as
measured by tumor growth and survival rates of intralesional chemotherapy for patients
with recurrent SCLC after standard treatment.
cancer in two fashions:
1. to implement a prospective clinical trial to test the feasibility and efficacy of
intralesional chemotherapy as consolidative therapy immediately following standard
systemic chemotherapy and radiation therapy for patients with limited stage SCLC by
comparing tumor growth and survival rates of the treatment group and compare the
outcomes to historical controls
2. to implement a prospective clinical trial to test the feasibility and efficacy as
measured by tumor growth and survival rates of intralesional chemotherapy for patients
with recurrent SCLC after standard treatment.
Subjects will receive standard of care treatment for SCLC with added treatment of Cisplatin
injection via endobronchial ultrasound aided bronchoscopy a total of four times. Outcome
measurements of tumor growth and survival will be compared to subjects receiving standard of
care treatment only.
injection via endobronchial ultrasound aided bronchoscopy a total of four times. Outcome
measurements of tumor growth and survival will be compared to subjects receiving standard of
care treatment only.
Inclusion Criteria: Competent adult English speaking subjects
- With limited stage SCLC who have completed standard of care treatment who are
responders with no evidence of disseminated disease other than CNS metastasis,
- With recurrent disseminated SCLC after standard of care treatment with symptoms
related to central tumor obstruction,
- With recurrent limited stage SCLC with mediastinal/hilar recurrence not previously
treated with intratumoral cisplatin
Exclusion Criteria:
- Subjects who do not meet the inclusion criteria
- Subjects who, in the opinion of the investigator, are at risk undergoing a
bronchoscopy
We found this trial at
1
site
University of Florida The University of Florida (UF) is a major, public, comprehensive, land-grant, research...
Click here to add this to my saved trials
